Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea

Pediatric Blood and Cancer

Volumn 60, Issue 8, 2013, Pages 1333-1337

  Lebensburger, Jeffrey D ^a   Sidonio, Robert F ^b   Debaun, Michael R ^b   Safford, Monika M ^c   Howard, Thomas H ^a   Scarinci, Isabel C ^c  

^a University of Alabama at Birmingham   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Clinical trials; Psychosocial; Sickle cell anemia; Sickle cell disease

Indexed keywords

HYDROXYUREA;

ACUTE TOXICITY; ADULT; AFRICAN AMERICAN; ARTICLE; BONE MARROW SUPPRESSION; CHILDHOOD DISEASE; CLINICAL TRIAL (TOPIC); COMPREHENSION; EDUCATION; EMOTIONAL STRESS; EQUIPOISE; FEMALE; HUMAN; MALE; PARENT; PRIORITY JOURNAL; RANDOMIZATION; RISK; SICKLE CELL ANEMIA; STUDY DESIGN; THERAPY EFFECT;

EID: 84879232521     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24486     Document Type: Article

References (20)

1. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995; 127:685-690.
2. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593-1599.
3. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5-11.
4. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317-1322.
5. Penberthy L, Brown R, Wilson-Genderson M, et al. Barriers to therapeutic clinical trials enrollment: Differences between African-American and White cancer patients identified at the time of eligibility assessment. Clin Trials 2012; 9:788-799.
6. Advani AS, Atkeson B, Brown CL, et al. Barriers to the participation of African-American patients with cancer in clinical trials: A pilot study. Cancer 2003; 97:1499-1506.
7. Braunstein JB, Sherber NS, Schulman SP, et al. Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials. Medicine (Baltimore) 2008; 87:1-9.
8. Kitterman DR, Cheng SK, Dilts DM, et al. The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. Acad Med 2011; 86:1360-1366.
9. Quinn CT, Stuart MJ, Kesler K, et al. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol 2011; 155:263-267.
10. Scarinci IC, Bandura L, Hidalgo B, et al. Development of a theory-based (PEN-3 and health belief model), culturally relevant intervention on cervical cancer prevention among Latina immigrants using intervention mapping. Health Promot Pract 2012; 13:29-40.
11. Merriam SB. Qualitative research: A guide to design and implementation, Vol. 2. San Francisco: Jossey-Bass; 2009. pp. 169-207.
12. Saldana J. The coding manual for qualitative researchers. Thousand Oaks, CA: Sage Publications; 2012.
13. Creswell JW. Qualitative inquiry & research design: Choosing among five approaches, Vol. xvii. 2nd edition. Thousand Oaks: Sage Publications; 2007. pp. 202-209.
14. Styles L, Wager CG, Labotka RJ, et al. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: Results of a feasibility study (PROACTIVE). Br J Haematol 2012; 157:627-636.
15. Peters-Lawrence MH, Bell MC, Hsu LL, et al. Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials 2012; 33:291-297.
16. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663-1672.
17. Wynn L, Miller S, Faughnan L, et al. Recruitment of infants with sickle cell anemia to a Phase III trial: Data from the BABY HUG study. Contemp Clin Trials 31:558-563.
18. Ware RE, Schultz WH, Yovetich N, et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer 2011; 57:1011-1017.
19. DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: Low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 2012; 119:3684-3690.
20. Byrd GS, Edwards CL, Kelkar VA, et al. Recruiting intergenerational African American males for biomedical research Studies: A major research challenge. J Natl Med Assoc 2011; 103:480-487.